Alkermes appoints two directors
Richard Gaynor joined Neon Therapeutics in 2016 as its President of Research and Development.
Prior to joining Neon, Dr. Gaynor began his industry career at Eli Lilly and Company, where he spent 15 years in clinical development and medical affairs roles, including as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology from 2013 until his departure in 2016.
During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with GE, AstraZeneca and Bristol-Myers Squibb.
Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine for nine years, followed by 11 years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center.
He holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at the UCLA School of Medicine.
As the former Chief Financial Officer and Senior Vice President of PerkinElmer, Inc., a life sciences diagnostics, discovery and analytical solutions company, Frank Anders Wilson oversaw the organization's growth strategy from 2009 until his retirement in 2018.
Prior to joining PerkinElmer, Inc., Mr. Wilson held key business development and finance roles over 12 years at Danaher Corporation, a global science and technology conglomerate, including Corporate Vice President of Investor Relations.
Prior to Danaher, he worked for several years at AlliedSignal, Inc., now Honeywell International Inc., where he served as Vice President of Finance and Chief Financial Officer for the Commercial Avionics Systems division.
Prior to AlliedSignal, Mr. Wilson's work included financial and controllership positions of increasing responsibility at PepsiCo, Inc., as well as roles at E.F. Hutton and Company, and KPMG Peat Marwick.
Mr. Wilson is a Certified Public Accountant.
He has served as a member of the Board of Directors of Cabot Corporation, a public global specialty chemicals and performance materials company, since 2018. ■